Alkermes plc logo ALKS - Alkermes plc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 16
HOLD 10
SELL 3
STRONG
SELL 0
| PRICE TARGET: $52.60 DETAILS
HIGH: $65.00
LOW: $43.00
MEDIAN: $54.00
CONSENSUS: $52.60
UPSIDE: 1.94%

Stock News

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Alkermes to Report Second Quarter Financial Results on July 28, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast.

Jul 14, 2026 12:00 PM • businesswire.com
Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approxim.

Jul 13, 2026 03:00 AM • businesswire.com
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.

Jun 19, 2026 11:49 AM • seekingalpha.com
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study's dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared to placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight in adults with NT2 (n=.

Jun 17, 2026 12:15 PM • businesswire.com
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug designations (ODD) from leading regulatory bodies in the U.S. and Europe. The U.S. Food and Drug Administration (FDA) has granted ODD to alixorexton for the treatment of IH, and the Euro.

Jun 15, 2026 03:00 AM • businesswire.com
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes' sleep portfolio following the acquisition of Avadel.

Jun 04, 2026 03:00 AM • businesswire.com
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes' proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r.

May 26, 2026 03:00 AM • businesswire.com
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes' ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych.

May 21, 2026 03:00 AM • businesswire.com
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension in adults with idiopathic hypersomnia (IH). LUMRYZ met the study's primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by t.

May 12, 2026 03:00 AM • businesswire.com

Price Targets